Innacell γδ

Innacell γδ is an **autologous cell therapy product** based on ex-vivo expanded γ9δ2 T lymphocytes, derived from a patient's own peripheral blood mononuclear cells (PBMCs) through stimulation with BrHPP (IPH1101, Phosphostim) and interleukin 2 (IL-2)[1][2]. The resulting product contains a high proportion of effector/memory γ9δ2 T cells, which display direct cytotoxicity against tumor cells, notably **renal cell carcinoma**[1][2]. Innacell γδ is designed as an immunotherapeutic approach for metastatic renal cell carcinoma (mRCC) and potentially other cancer indications refractory to conventional therapies. The cells are administered by intravenous infusion, often with co-administration of low-dose IL-2 to promote survival and activity of the infused cells in vivo[1]. The primary mechanism involves **adoptive transfer of cytotoxic γ9δ2 T cells** to target and kill cancer cells.

Brand names

Innacell γδ

Other names

Innacell gammadeltaInnacell gamma-delta therapyγ9δ2 cell therapy product